These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25228550)

  • 41. Bendamustine: a new therapeutic option for hematologic malignancies.
    Cheson BD
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
    [No Abstract]   [Full Text] [Related]  

  • 42. EPHA3 as a novel therapeutic target in the hematological malignancies.
    Keane N; Freeman C; Swords R; Giles FJ
    Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New targets for hematologic malignancies.
    Bradner J
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):375-6. PubMed ID: 24472807
    [No Abstract]   [Full Text] [Related]  

  • 44. Application of vitamin D and derivatives in hematological malignancies.
    Kim M; Mirandola L; Pandey A; Nguyen DD; Jenkins MR; Turcel M; Cobos E; Chiriva-Internati M
    Cancer Lett; 2012 Jun; 319(1):8-22. PubMed ID: 22193723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigational antibody-drug conjugates for hematological malignancies.
    Polson AG; Ho WY; Ramakrishnan V
    Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiogenesis and antiangiogenic therapy in hematologic malignancies.
    Dong X; Han ZC; Yang R
    Crit Rev Oncol Hematol; 2007 May; 62(2):105-18. PubMed ID: 17188504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hematologic Malignancies/Pediatric Malignancies New Therapeutic Strategy for Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2018 May; 45(5):793-794. PubMed ID: 30026439
    [No Abstract]   [Full Text] [Related]  

  • 48. [Clinical study of double units unrelated cord blood transplantation in adult patients with hematological malignancies].
    Yin Y; Ren HY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Wang MJ; Wang LH; Li Y
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):73-7. PubMed ID: 18681304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surgical complications in hematological malignancies.
    Nenova I; Grudeva-Popova J; Dimov R; Chapkunov A; Mihailov H
    Folia Med (Plovdiv); 1999; 41(2):16-21. PubMed ID: 10534908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
    Ravandi F; Talpaz M; Estrov Z
    Clin Cancer Res; 2003 Feb; 9(2):535-50. PubMed ID: 12576416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Viral findings during febrile episodes after cytotoxic chemotherapy in patients with hematological malignancies.
    Rintala EM; Nikoskelainen J; Ziegler T; Jussila R
    Eur J Clin Microbiol Infect Dis; 1998 Aug; 17(8):593-4. PubMed ID: 9796663
    [No Abstract]   [Full Text] [Related]  

  • 53. Management of hematological malignancies in patients affected by renal failure.
    Niscola P; Vischini G; Tendas A; Scaramucci L; Giovannini M; Bondanini F; Romani C; Brunetti GA; Cartoni C; Cupelli L; Ferrannini M; Perrotti A; Del Poeta G; Palumbo R; de Fabritiis P
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):415-32. PubMed ID: 21417855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A role of new molecular-target drugs for hematologic malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2015 May; 42(5):548-9. PubMed ID: 26054087
    [No Abstract]   [Full Text] [Related]  

  • 55. New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction.
    Kantarjian H
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):1-2. PubMed ID: 9779875
    [No Abstract]   [Full Text] [Related]  

  • 56. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
    Craver C; Gayle J; Balu S; Buchner D
    J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.
    Zhan F; Zangari M; Qiu L
    Biomed Res Int; 2015; 2015():384575. PubMed ID: 26000289
    [No Abstract]   [Full Text] [Related]  

  • 59. Present status and perspectives regarding the therapeutic strategy for acute myeloid leukemia, non-Hodgkin's lymphoma and multiple myeloma in the elderly.
    Ohta M
    Geriatr Gerontol Int; 2009 Jun; 9(2):115-23. PubMed ID: 19740353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of hematological malignancies during pregnancy.
    Rizack T; Mega A; Legare R; Castillo J
    Am J Hematol; 2009 Dec; 84(12):830-41. PubMed ID: 19844988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.